Search
Skip to Search Results-
Spring 2018
Renal cell carcinoma comprises approximately 2-3% of all malignancies, with the majority, approximately 70%, being clear cell renal cell carcinoma (ccRCC). ccRCC features many cancer hallmarks such as suppressed mitochondrial glucose oxidation, apoptosis-resistance, angiogenesis, immune evasion,...
-
Spring 2018
Renal cell carcinoma comprises approximately 2-3% of all malignancies, with the majority, approximately 70%, being clear cell renal cell carcinoma (ccRCC). ccRCC features many cancer hallmarks such as suppressed mitochondrial glucose oxidation, apoptosis-resistance, angiogenesis, immune evasion,...
-
Utilizing Positron Emission Tomography to Detect Functional Changes Following Drug Therapy in a Renal Cell Carcinoma Mouse Model
DownloadSpring 2013
Sunitinib is currently the first line drug therapy for metastasizing renal cell carcinoma (RCC). It has been shown to have a profound effect on tumor angiogenesis leading to modifications of the tumor’s microenvironment. Tumor hypoxia plays an important role in the metastatic potential of a solid...